Salarius Pharmaceuticals Inc Total Liabilities

Latest as of September 2025: $1.85 Million USD

Salarius Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Salarius Pharmaceuticals Inc (SLRX) has total liabilities worth $1.85 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Salarius Pharmaceuticals Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Salarius Pharmaceuticals Inc (2014–2024)

Total liabilities of Salarius Pharmaceuticals Inc from 2014 to 2024. This chart illustrates how Salarius Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Salarius Pharmaceuticals Inc (SLRX) investment intensity to see how much of total assets are deployed in long-term investments.

Salarius Pharmaceuticals Inc Competitors by Total Liabilities

The table below lists competitors of Salarius Pharmaceuticals Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Aurora Energy Metals Ltd AU:1AE	Australia	AU$208.63K
Bio Green Med Solution, Inc. NASDAQ:BGMS	USA	$1.34 Million
YOLO GROUP S.P.A. O.N. F:X2Y	Germany	€15.34 Million
CASA DE BUCOVINA-CLUB DE MUNTE RO:BCM	Romania	RON121.74K
Bhuwanatala Indah Permai Tbk JK:BIPP	Indonesia	Rp847.08 Billion
C&C Group plc LSE:CCR	UK	GBX812.48 Million
JATCORP LTD. F:3J2	Germany	€14.53 Million

Liability Composition Analysis (2014–2024)

This chart breaks down Salarius Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Salarius Pharmaceuticals Inc asset portfolio.

Liquidity & Leverage Metrics

Salarius Pharmaceuticals Inc Total Liabilities Ratios Explained

Salarius Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	5.49	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.44	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.30	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Salarius Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Salarius Pharmaceuticals Inc (2014–2024)

The table below shows the annual total liabilities of Salarius Pharmaceuticals Inc from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	$1.51 Million	+16.32%
2023-12-31	$1.30 Million	-69.55%
2022-12-31	$4.27 Million	+102.10%
2021-12-31	$2.11 Million	-23.88%
2020-12-31	$2.77 Million	-16.31%
2019-12-31	$3.31 Million	+199.33%
2018-12-31	$1.11 Million	-81.20%
2017-12-31	$5.89 Million	+51.04%
2016-12-31	$3.90 Million	+35.45%
2015-12-31	$2.88 Million	-93.17%
2014-12-31	$42.15 Million	--

About Salarius Pharmaceuticals Inc

NASDAQ:SLRX USA Biotechnology

Market Cap

$4.81 Million

Market Cap Rank

#28602 Global

#5882 in USA

Share Price

$0.82

Change (1 day)

-2.40%

52-Week Range

$0.54 - $3.01

All Time High

$65800.00